NEW YORK (Reuters Health) - After approximately 8 years,
postmenopausal women with hormone-sensitive
breast cancer who received (Arimidex), generically known as anastrazole, had a lower risk of recurrence than women taking tamoxifen, investigators reported at the annual meeting of the San Antonio Breast Cancer Symposium.
After an average of 68 months, women on Arimidex had a 15-percent greater disease-free survival and a 25-percent longer time to disease recurrence than women on tamoxifen.